Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:8923 |
Name | skin melanoma |
Definition | A skin cancer that has_material_basis_in melanocytes. |
Source | DiseaseOntology.org |
Alt Ids | DOID:10043 DOID:10051 DOID:0050609 DOID:10046 DOID:10052 DOID:10055 DOID:8922 |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin melanoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01107665 | Phase II | Paclitaxel + Pazopanib | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | Completed | USA | 0 |
NCT01693068 | Phase II | Dacarbazine Pimasertib | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT02203604 | Phase II | Aldesleukin + Ipilimumab | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | 1 |
NCT02535078 | Phase Ib/II | Durvalumab Tebentafusp Tremelimumab | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | Recruiting | USA | 0 |
NCT02581930 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma | Active, not recruiting | USA | 0 |
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02680184 | Phase I | Pembrolizumab + Vidutolimod | Clinical Study of CMP-001 in Combination With Pembrolizumab | Completed | USA | 0 |
NCT02731729 | Phase II | Ipilimumab Nivolumab | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | Completed | USA | 0 |
NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ESP | 1 |
NCT03084640 | Phase Ib/II | Pembrolizumab + Vidutolimod | Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma | Completed | USA | 0 |
NCT03089606 | Phase II | Pembrolizumab | Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker | Active, not recruiting | USA | 0 |
NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Recruiting | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT03278665 | Phase Ib/II | Domatinostat + Pembrolizumab | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) | Completed | ITA | DEU | 0 |
NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | AUS | 1 |
NCT03405155 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03551626 | Phase III | Dabrafenib + Trametinib | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) | Completed | ITA | GBR | FRA | CAN | AUS | 18 |
NCT03553836 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT03618641 | Phase II | Nivolumab + Vidutolimod | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | Active, not recruiting | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | GBR | FRA | ESP | 2 |
NCT03754179 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2) | Unknown status | BEL | 0 |
NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
NCT03842943 | Phase II | Pembrolizumab + Talimogene laherparepvec | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | Recruiting | USA | 0 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Active, not recruiting | USA | ESP | CAN | BEL | 1 |
NCT03875079 | Phase I | Pembrolizumab + RO6874281 | A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT03897881 | Phase II | mRNA-4157 + Pembrolizumab Pembrolizumab | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) | Recruiting | USA | AUS | 0 |
NCT03898908 | Phase II | Binimetinib + Encorafenib | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) | Recruiting | ESP | 0 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
NCT03972046 | Phase II | Dabrafenib + Talimogene laherparepvec + Trametinib | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | Withdrawn | USA | 0 |
NCT03991741 | Phase I | Aldesleukin | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | Recruiting | USA | 0 |
NCT04007588 | Phase II | Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | Withdrawn | USA | 0 |
NCT04020809 | Phase I | Atezolizumab | Neoadjuvant Atezolizumab in Cutaneous Melanoma | Recruiting | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
NCT04074096 | Phase II | Binimetinib + Encorafenib + Pembrolizumab | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) | Recruiting | FRA | 0 |
NCT04099251 | Phase III | Nivolumab | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 10 |
NCT04135352 | Phase I | Pembrolizumab + V938 | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | Terminated | USA | CAN | 1 |
NCT04136834 | Phase I | Pegtomarginase | A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) | Unknown status | USA | 0 |
NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Recruiting | USA | 0 |
NCT04207086 | Phase II | Lenvatinib + Pembrolizumab Pembrolizumab | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) | Recruiting | AUS | 0 |
NCT04221438 | Phase II | Binimetinib + Encorafenib | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | Active, not recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04261439 | Phase I | NIZ985 NIZ985 + Spartalizumab | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | Active, not recruiting | USA | ITA | ESP | DEU | BEL | 2 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | 4 |
NCT04356729 | Phase II | Atezolizumab + Bevacizumab | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
NCT04375527 | Phase II | Binimetinib + Nivolumab | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | Recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Recruiting | USA | 9 |
NCT04401995 | Phase II | Nivolumab Nivolumab + Vidutolimod | Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab | Recruiting | USA | 0 |
NCT04410445 | Phase III | Nivolumab Nivolumab + NKTR-214 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS | 9 |
NCT04455503 | Phase Ib/II | EVX-02 + Nivolumab | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Active, not recruiting | AUS | 0 |
NCT04493203 | Phase II | Axitinib + Nivolumab | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | Recruiting | USA | 0 |
NCT04495010 | Phase II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) | Withdrawn | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 7 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04526899 | Phase II | Cemiplimab BNT111 BNT111 + Cemiplimab | Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | Recruiting | USA | ITA | GBR | ESP | DEU | AUS | 1 |
NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | CAN | BEL | AUS | 1 |
NCT04570332 | Phase II | BO-112 + Pembrolizumab | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) | Active, not recruiting | FRA | ESP | 0 |
NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Recruiting | USA | 0 |
NCT04592653 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) | Recruiting | USA | 0 |
NCT04609566 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04620603 | Phase Ib/II | Nivolumab | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | Recruiting | USA | 0 |
NCT04657991 | Phase III | Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 18 |
NCT04697576 | Phase I | Nivolumab Pembrolizumab Ipilimumab | Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma | Recruiting | USA | 0 |
NCT04703426 | Phase II | Pembrolizumab + Sargramostim | Sargramostim (GM-CSF) + PD-1 | Withdrawn | 0 | |
NCT04759846 | Phase I | Binimetinib + Encorafenib | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Withdrawn | ITA | ESP | 1 |
NCT04830124 | Phase II | ALKS 4230 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 2 |
NCT04835805 | Phase I | Belvarafenib + Cobimetinib + Nivolumab Belvarafenib + Cobimetinib Belvarafenib | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | Recruiting | USA | DEU | CAN | AUS | 2 |
NCT04901988 | Phase II | Nivolumab | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) | Terminated | GBR | 0 |
NCT04930783 | Phase I | CDX-301 + Nivolumab + Poly ICLC | NeoVax + CDX-301 and Nivolumab in Advanced Melanoma | Recruiting | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT04995094 | Phase II | Pembrolizumab Pembrolizumab + PGG beta-glucan | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | Withdrawn | USA | 0 |
NCT05050006 | Phase II | ITIL-168 | ITIL-168 in Advanced Melanoma (DELTA-1) | Terminated | USA | GBR | CAN | 0 |
NCT05060003 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | Recruiting | USA | 0 |
NCT05061017 | Phase II | Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | Recruiting | USA | 0 |
NCT05061134 | Phase II | Ceralasertib + Durvalumab Ceralasertib | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
NCT05130177 | Phase II | AB154 + Zimberelimab | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT05200143 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Recruiting | USA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 7 |
NCT05270044 | Phase III | Binimetinib + Encorafenib | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD) | Recruiting | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 14 |
NCT05315258 | Phase II | Tebentafusp | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) | Recruiting | GBR | 0 |
NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Recruiting | USA | FRA | ESP | DEU | AUS | 2 |
NCT05418972 | Phase II | Nivolumab and relatlimab-rmbw | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) | Not yet recruiting | AUS | 0 |
NCT05479812 | Phase I | WTX-124 Pembrolizumab + WTX-124 | Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Recruiting | USA | 0 |
NCT05492682 | Phase I | Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Recruiting | DEU | 0 |
NCT05529316 | Phase II | AGEN1181 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05544929 | Phase I | KFA115 + Tislelizumab KFA115 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers | Recruiting | CAN | 3 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | 0 |
NCT05572463 | Phase Ib/II | IBI110 + Sintilimab | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | Withdrawn | USA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05578872 | Phase Ib/II | ANV419 + Ipilimumab ANV419 + Pembrolizumab ANV419 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101). | Recruiting | USA | FRA | ESP | DEU | 0 |
NCT05580770 | Phase Ib/II | BGB3245 + PD-0325901 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05665595 | Phase III | Pembrolizumab MK-7684A | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | Recruiting | USA | AUS | 10 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Not yet recruiting | USA | GBR | ESP | 0 |
NCT05764395 | Phase II | Pembrolizumab + Rigosertib | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |